Exelixis Inc (EXEL)
Current ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Total current assets | US$ in thousands | 1,467,580 | 1,317,960 | 1,618,760 | 1,834,750 | 1,445,400 |
| Total current liabilities | US$ in thousands | 403,769 | 394,277 | 324,359 | 337,590 | 204,658 |
| Current ratio | 3.63 | 3.34 | 4.99 | 5.43 | 7.06 |
December 31, 2024 calculation
Current ratio = Total current assets ÷ Total current liabilities
= $1,467,580K ÷ $403,769K
= 3.63
The current ratio of Exelixis Inc has experienced a declining trend over the past five years. Starting at a robust 7.06 in December 31, 2020, the ratio has decreased to 3.63 as of December 31, 2024. This indicates that the company's current assets are becoming less sufficient to cover its current liabilities, raising concerns about its short-term liquidity position. Further monitoring of Exelixis Inc's ability to meet its short-term obligations may be prudent as the current ratio continues to decrease.
Peer comparison
Dec 31, 2024
Company name
Symbol
Current ratio
Exelixis Inc
EXEL
3.63
Arrowhead Pharmaceuticals Inc
ARWR
6.74
Charles River Laboratories
CRL
1.41
Incyte Corporation
INCY
1.97
IQVIA Holdings Inc
IQV
0.84
Medpace Holdings Inc
MEDP
0.93